"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

The decision to cancel almost $500 million dollars in U.S. funding for the development of messenger RNA vaccines is dangerous ...

Jerome Adams, the U.S. Surgeon General under President Trump's first term, is criticizing his administration's cuts to mRNA vaccine research.